Health-care Disruptors: New Models Changing the Landscape

Parkinson's Disease and Telemedicine (Dr. Ray Dorsey, University of Rochester)

• Neurological disorders are the leading global source of disability; Parkinson's disease is the fastest-growing, with cases doubling globally from 1990–2015 and projected to double again in the next 25 years.
• Only ~40% of Medicare beneficiaries with Parkinson's disease see a neurologist; those who do not receive care have worse health outcomes and higher mortality rates.
• The University of Rochester provides home-based video care to >300 New Yorkers, where the average patient age is >70, 59% live in health professional shortage areas, and 20% are homebound.
• Satisfaction rates for the home-based care model are 98%.
• Telemedicine eliminates a 4-hour, 15-minute average travel time (round trip) required for a 30-minute in-person clinic visit.
• Medicare reimbursement for telemedicine visits in the home is $0, compared to ~$200 for hospital-based clinics and ~$100 for community clinics.
• The panel identified a failure to address racial disparities in telemedicine uptake, with current studies showing 97% white participation.

Generic Drug Supply and CivicaRx (Dan Liljenquist, Intermountain Healthcare)

• Hospital systems currently manage ~200 shortages of essential generic medications driven by market consolidation and monopoly-like sole-source dominance in specific drug markets.
• Monopolies maximize profit by restraining supply; the lack of competition has led to unpredictable drug availability and operational drag for hospital staff.
• Inadequate access to specific broad-spectrum antibiotics can cause hospital-acquired infection mortality rates to jump from 10% to 60%.
• CivicaRx was formed as a Delaware non-stock nonprofit corporation to act as a "public utility" for essential generic manufacturing, utilizing a "take-or-pay" contract model to stabilize demand.
• Governing members include three major philanthropies (Laura and John Arnold Foundation, Gary and Mary West Foundation, Peterson Center on Healthcare) and seven health systems (Intermountain, SSM Health, Trinity Health, HCA, Catholic Health Initiatives, Providence St. Joseph Health, Mayo Clinic).
• The model aims to lower market prices by >50% and function as a "market of last resort" without seeking special government favors or antitrust exemptions.
• The organization is structured to be impossible to monetize, requiring a unanimous vote of all governing members to ever convert to a for-profit status.

Food as Medicine (Dr. Andrea Feinberg, Geisinger Innovation)

• 90% of diabetes cases in the U.S. are Type 2, a lifestyle condition; the panel noted that 20% of health outcomes are driven by medical care, while ~70% are driven by social determinants (food, housing, transportation).
• In 2016, Geisinger launched the "Fresh Food Pharmacy," providing free, nutritious food to food-insecure patients with uncontrolled Type 2 diabetes alongside 20 hours of disease education.
• Early results showed significant drops in hemoglobin A1c within 6–12 weeks, with some patients developing hypoglycemia within a week due to improved diet.
• The pilot program resulted in a 25% reduction in emergency department visits and a 75% reduction in hospitalizations.
• Cost analysis of pilot patients showed a two-thirds reduction in total costs.
• The program aims to provide 1.5 million meals annually by the end of 2019.
• Current federal regulations (CMS) prohibit health systems from targeting food assistance to patients based on social need rather than specific ICD-10 billable codes, limiting scalability.
• The model faces a barrier where regulations limit the value of goods (like food) that can be provided to patients to under $75 annually, despite the high cost of necessary medications.

Precision Medicine and Data Integration (Dr. Joel Dudley, Mount Sinai)

• Current AI applications in healthcare are largely limited to imaging and research; the panel argued the industry is building "mechanical horses to pull a carriage" because existing data frameworks are incompatible with new algorithms.
• The primary bottleneck for AI in precision medicine is not a lack of algorithms, but the lack of structured, high-quality data to feed them.
• Mount Sinai is focusing on redesigning care environments to generate "health records" (data on wellness) rather than just "disease records" to predict disease transitions.
• Integrating clinical and financial data within large institutions (e.g., a $9 billion system) is a major challenge due to fragmented software and data silos.
• Mount Sinai created a "precision health enterprise group" reporting directly to the CEO to avoid incremental improvements and instead drive 10X innovation via new products and services.
• Apple's involvement in pushing the FHIR (Fast Healthcare Interoperability Resources) protocol has accelerated EHR data liquidity, which was previously resistant due to EHR vendor inertia.
• Clinical trials using Apple Research Kit have enrolled tens of thousands of participants across 40 states, but face high attrition rates similar to traditional trials.

Scalability, Barriers, and Future Outlook

• Scalability of Home Care: While educational content (e.g., "Parkinson TV") can scale globally via social media, personalized care elements (parenting analogy) should not be scaled, as it risks treating patients as "widgets."
• Global Expansion: The Fresh Food Pharmacy model is being considered for international expansion, though the challenge lies in transmitting lifestyle medicine knowledge rather than just technology; a partnership with the Helmholtz Institute in Germany is being planned.
• Regulatory Barriers: CivicaRx faces no antitrust concerns because it operates only in markets with non-functioning monopolies and represents a collective purchasing action by customers (hospitals).
• Payment Reform: Sustaining these models requires political will to change Medicare reimbursement structures (e.g., paying for home telemedicine) and adjusting regulations to allow food to be prescribed as medicine based on social need rather than diagnosis codes.
• Equity: There is a risk that digital health solutions exacerbate the "digital divide" based on income and education, though evidence suggests underserved populations may engage more with mobile health as their primary communication tool.
• Market Dynamics: Private capital is unwilling to enter generic drug markets due to high fixed costs and low marginal costs; CivicaRx proposes a collective vertical integration model to solve this market failure without government bailouts.